Adam S. Mostafa
Known title: Chief Financial OfficerCIK: 0001738081
Associated companies
Transaction History
| XFOR | ▲ Buy | Grant | 850,000 | $0 | 2/12/2025 | View on chart |
| XFOR | ▼ Sell | Open Market | 74,773 | $34K | 1/24/2025 | View on chart |
| XFOR | ▲ Buy | Grant | 74,773 | $0 | 1/23/2025 | View on chart |
| XFOR | ▼ Sell | Open Market | 230,645 | $127K | 10/7/2024 | View on chart |
| XFOR | ▲ Buy | Grant | 230,645 | $0 | 10/4/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 52,500 | $46K | 3/11/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 27,721 | $28K | 2/12/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 230,645 | $168K | 11/1/2023 | View on chart |
| XFOR | ▲ Buy | Grant | 230,645 | $0 | 10/31/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 2,641 | $5K | 6/30/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 5,417 | $10K | 6/23/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 5,417 | $12K | 6/15/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 52,500 | $44K | 3/10/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 27,721 | $26K | 2/13/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 10,834 | — | 8/17/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 2,641 | — | 6/30/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 5,416 | — | 6/24/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 5,416 | — | 6/16/2022 | View on chart |
| XFOR | ▲ Buy | Grant | 105,000 | $0 | 3/1/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 27,721 | — | 2/11/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 10,832 | $55K | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround
X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround. X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.